21.10.2023 16:59:22
|
AstraZeneca: 59% Of Patients Treated With Tagrisso + Chemotherapy Had Complete Brain Tumor Responses
(RTTNews) - AstraZeneca (AZN.L, AZN) said that results from a prespecified exploratory analysis of the FLAURA2 Phase III trial showed the company's Tagrisso(osimertinib) with the addition of chemotherapy demonstrated a 42% improvement in central nervous system (CNS) progression-free survival (PFS), compared to Tagrisso alone for patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) and brain metastases at baseline. 59% of the patients treated with TAGRISSO plus chemotherapy had complete brain tumor responses in FLAURA2 Phase III trial.
In this group of patients, Tagrisso with the addition of chemotherapy reduced the risk of CNS disease progression or death by 42% compared to Tagrisso alone as assessed by blinded independent central review or BICR.
With two years of follow-up, 74% of patients treated with Tagrisso plus chemotherapy had not experienced CNS disease progression or death versus 54% of patients treated with Tagrisso monotherapy. Results also showed a higher proportion of patients demonstrated CNS complete response (CR) with Tagrisso plus chemotherapy (59%) versus Tagrisso alone (43%).
For More Such Health News, visit rttnews.com

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLC (spons. ADRs)mehr Nachrichten
21.03.25 |
Pluszeichen in New York: NASDAQ 100 zeigt sich zum Handelsende fester (finanzen.at) | |
21.03.25 |
NASDAQ-Handel NASDAQ 100 in Rot (finanzen.at) | |
21.03.25 |
Gewinne in New York: NASDAQ 100 am Mittag im Aufwind (finanzen.at) | |
21.03.25 |
Forschungszentrum in Peking: AstraZeneca-Aktie negativ (Dow Jones) | |
21.03.25 |
Zurückhaltung in New York: NASDAQ 100 zum Handelsstart leichter (finanzen.at) | |
20.03.25 |
Anleger in New York halten sich zurück: NASDAQ 100 gibt letztendlich nach (finanzen.at) | |
20.03.25 |
NASDAQ 100-Handel aktuell: NASDAQ 100 liegt am Donnerstagnachmittag im Minus (finanzen.at) | |
20.03.25 |
Schwache Performance in New York: NASDAQ 100 liegt am Donnerstagmittag im Minus (finanzen.at) |
Analysen zu AstraZeneca PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 69,50 | -1,42% |
|